<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785809</url>
  </required_header>
  <id_info>
    <org_study_id>H-16021266</org_study_id>
    <nct_id>NCT02785809</nct_id>
  </id_info>
  <brief_title>Ovarian Function and Reserve Parameters After Discontinuation of Long-term Use of Oral Contraception</brief_title>
  <official_title>Recovery of Ovarian Function and Reserve Parameters After Discontinuation of Long-term Use of Oral Contraception: Is the Recovery Period Related to AMH?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Nyboe Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether there is a correlation between anti-Müllerian
      hormone during long-term use of combined oral contraceptives and the recovery time before
      recovered menstrual cycle after discontinuation of oral contraceptives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Hormonal contraception is widely used among women worldwide; 50-89% of all women in the
      Western countries use oral contraception at some point in their lives. Oral contraceptives
      (OC) suppress the hypothalamic-pituitary-ovarian axis through a negative feedback of ethinyl
      estradiol and progestins and thereby potentially influence the markers of ovarian reserve due
      to a suppressed release of gonadotropins, which will impair the growth of antral follicles.

      Methods and Materials:

      Participants for this studies will be included through the Fertility Assessment and
      Counseling Clinic, Rigshospitalet, Herlev- and Hvidovre Hospital.

      Inclusion criteria: Use of oral contraception (for study 3 at least during the last three
      years).

      Exclusion criteria: Known infertility, known thyroid disease.

      Aims:

      Study 3: Investigate the ovarian reserve markers after discontinuation of OC over a period of
      three months in women with a history of long-term OC use. The women will be followed with
      serial ultrasounds and blood samples and will complete a menstrual calendar.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time for recovered menstrual cycle after discontinuation of oral contraception</measure>
    <time_frame>6 months after discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ovarian reserve parameters before and after discontinuation of combined oral contraception</measure>
    <time_frame>3 months after discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between suppression of the pituitary gonodal axis during use of oral contraceptives and time for recovered menstrual cycle</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Oral Contraceptives</condition>
  <condition>Long-term Use</condition>
  <condition>AMH</condition>
  <condition>Ovarian Reserve Parameters</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pausing oral contraceptive</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Withdrawal of bloodsamples (6 within a three months period) for analyses of reproductive
      hormones.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a history of long term use of combine oral contraception for at least 3 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum three years of oral contraceptives.

        Exclusion Criteria:

          -  Known infertility, known thyroid disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selma K Landersoe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, The Fertility Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Selma K Landersoe, MD</last_name>
    <phone>+45 35 45 49 51</phone>
    <email>selma.kloeve.landersoe.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anders N Andersen, Professor, MD</last_name>
    <phone>+45 35 45 13 15</phone>
    <email>anders.nyboe.andersen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Rigshospitalet, The Fertility Clinic</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders N Andersen, Professor</last_name>
      <phone>+4535451315</phone>
      <email>anders.nyboe.andersen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Selma K Landersø, MD</last_name>
      <phone>+45 3545 4951</phone>
      <email>selma.kloeve.landersoe.01@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Selma K Landersoe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders N Andersen, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmill A, Fat DM, Boerma T, Temmerman M, Mathers C, Say L; United Nations Maternal Mortality Estimation Inter-Agency Group collaborators and technical advisory group. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet. 2016 Jan 30;387(10017):462-74. doi: 10.1016/S0140-6736(15)00838-7. Epub 2015 Nov 13.</citation>
    <PMID>26584737</PMID>
  </reference>
  <reference>
    <citation>van Heusden AM, Fauser BC. Residual ovarian activity during oral steroid contraception. Hum Reprod Update. 2002 Jul-Aug;8(4):345-58. Review.</citation>
    <PMID>12206469</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Anders Nyboe Andersen</investigator_full_name>
    <investigator_title>Professor M.D.</investigator_title>
  </responsible_party>
  <keyword>Oral contraceptives</keyword>
  <keyword>long-term use</keyword>
  <keyword>AMH</keyword>
  <keyword>Ovarian reserve parameters</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

